AMGN

AMGEN INC

Apr 05 • 04:00PM ET

272.41

+0.72 (+0.27%)

Company Profile

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients wi ... read more

Full Time Employees 26,700

Phone 805 447 1000

Website https://www.amgen.com

CEO Mr. Robert A. Bradway

IPO Date 1983-06-17

Sector Healthcare

Industry Drug Manufacturers - General

Address One Amgen Center Drive, Thousand Oaks, CA 91320-1799

Balance Sheet

Total Cash $8,810,000,000

Total Debt $57,381,000,000

Current Ratio 1.17

Quick Ratio 0.74

Profitability

Gross Margin 63.00%

Net Margin 17.39%

ROE 95.59%

ROA 6.64%

ROIC 10.45%

Balance Sheet

Total Cash $8,810,000,000

Total Debt $57,381,000,000

Current Ratio 1.17

Quick Ratio 0.74

Profitability

Gross Margin 63.00%

Net Margin 17.39%

ROE 95.59%

ROA 6.64%

ROIC 10.45%

Name	AMGEN INC	Sector	Healthcare	Currency	USD	Relative Volume	1.66	Market Cap	158147
Current Ratio	1.26	Dividend / Share	9.0	EPS	7.56	Revenue	33424000000	P/S	4.7
P/E	38.7	Beta	0.51	Income	4090000000	Volume	5250830	Average Volume	3166060
Distance to 200DMA	-4.04%	200 DMA	306.79	50 DMA	303.86	ROA	4.5	ROE	67.2
Distance to 50DMA	-3.12%	Return 1Y	10.58%	Return YTD	13.87%	Forward PE		Qtly Growth YOY
Debt/Eq	14.63	P/B	26.9	Dividend Yield	3.5%	Net Margin	12.24%	Payout Ratio	118.1

Performance

52 Week Range 118.1%

Distance to 200DMA 0.83%

Day Change Percent $2.25

Performance Week $2.25

Performance Month $2.25

Performance Quarter 2024-08-16

Performance YTD $2.25

Performance Year $2.25

Performance Range

Day

$196

Current

Low: High:

Month

$196

Current

Low: High:

Month

$196

Current

Low: High:

Month

$196

Current

Low: High:

Month

$196

Current

Low: High:

Balance Sheet

Total Cash $9,011,000,000

Total Debt $60,398,000,000

Current Ratio 1.32%

Quick Ratio 0.80%

Profitability

Valuation

Price to Earnings 24.70

Price to Book 23.61

Price to Sales 4.29

Price to Free Cash Flow 13.43

Dividends

Payout Ratio 82.79%

Dividend Yield 3.35%

Dividend Amount $2.25

Last Dividend Pay Date 2024-08-16

Last Dividend Paid $2.25

Performance

52 Week Range 118.1%

Distance to 200DMA 0.83%

Day Change Percent $2.25

Performance Week $2.25

Performance Month $2.25

Performance Quarter 2024-08-16

Performance YTD $2.25

Performance Year $2.25

Company Profile

Full Time Employees 26,700

Phone 805 447 1000

Website https://www.amgen.com

CEO Mr. Robert A. Bradway

IPO Date 1983-06-17

Sector Healthcare

Address One Amgen Center Drive, Thousand Oaks, CA 91320-1799

Histogram - Daily

Balance Sheet

Total Cash $9,011,000,000

Total Debt $60,398,000,000

Current Ratio 1.32%

Quick Ratio 0.80%

Profitability

Gross Margin 0.6050%

Net Margin 0.1300%

ROE 0.69%

ROA 0.04%

Company Profile

Full Time Employees 26,700

Phone 805 447 1000

Website https://www.amgen.com

CEO Mr. Robert A. Bradway

IPO Date 1983-06-17

Sector Healthcare

Address One Amgen Center Drive, Thousand Oaks, CA 91320-1799

Monthly Win Rate

Balance Sheet (Multi-Column Example)

	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023
Cash & Short Term Investments	53,775.0	65,171.0	61,801.0	67,150.0	73,100.0	61,555.0	62,482.0	55,872.0
Receivables	59,306.0	66,243.0	43,172.0	41,150.0	50,102.0	60,985.0	39,186.0	35,899.0
Inventory	6,911.0	7,286.0	6,165.0	6,232.0	6,511.0	6,331.0	7,351.0	7,482.0

Latest News

Amgen owes $406 million for monopolizing cholesterol drug market, US jury says

A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for engaging in anticompetitive behavior to increase sales of its cholesterol-re

2025-05-15 16:57:21 - reuters.com

Stock Of The Day: Amgen Slips With Healthcare Sector, But Signals Point To A Rev

The stock of Amgen Inc. AMGN is trading higher on Thursday. But along with the rest of the healthcare sector, it is still in a steep downtrend.

2025-05-15 15:25:17 - benzinga.com

Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Inno

Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent ® (alirocumab) from competing in the market

2025-05-15 14:02:00 - globenewswire.com

Amgen Inc. (AMGN) BofA Securities 2025 Healthcare Conference (Transcript)

Amgen Inc. (NASDAQ:AMGN ) BofA Securities 2025 Healthcare Conference Call May 14, 2025 12:20 PM ET Company Participants Peter Griffith - Executive Vice President and Chief Financial Officer Justin Cla

2025-05-14 16:21:22 - seekingalpha.com

Drug Stocks Recover as Trump's Order Proves Not as Bad as Feared

President Trump issues an executive order that will push drugmakers to offer prescription drugs to U.S. cash-pay consumers at lower prices.

2025-05-13 08:40:53 - zacks.com

Dr. Scott Gottlieb: What to expect from President Trump's executive order to low

Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.

2025-05-12 12:36:24 - youtube.com

Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet

President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t

2025-05-12 12:30:03 - seekingalpha.com

Pharma Stocks Hit by Trump's Vow to Cut US Prescription Drug Costs

The price cuts would see that U.S. consumers pay the same amount as the nation that pays the lowest price for that drug.

2025-05-12 10:41:06 - zacks.com

AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFEREN

THOUSAND OAKS, Calif. , May 9, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:20 a.m.

2025-05-09 16:01:00 - prnewswire.com

Pressure is still on the pharma sector, says Mizuho's Jared Holz

Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.

2025-05-08 19:23:04 - youtube.com

Amgen CEO Robert A. Bradway to Receive Honorary Degree from KGI

Claremont, CA, May 08, 2025 (GLOBE NEWSWIRE) -- During the Keck Graduate Institute commencement ceremony on May 17, 2025, Robert A. Bradway will receive an honorary Doctor of Philosophy in Applied Lif

2025-05-08 11:00:00 - globenewswire.com

Amgen's TEPEZZA®? (teprotumumab) Granted Marketing Authorisation as the First Ta

CAMBRIDGE, England--(BUSINESS WIRE)--Today, Amgen announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for TEPEZZA® (teprotumumab) as

2025-05-07 12:50:00 - businesswire.com

Here's Why Amgen (AMGN) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

2025-05-07 10:51:18 - zacks.com

Here's Why Amgen (AMGN) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

2025-05-06 10:46:28 - zacks.com

Amgen: Waiting Patiently For A Real Catalyst

Amgen Inc.'s diversified portfolio ensures steady revenue but modest growth, with no single drug contributing more than 15% to total revenue. Recent revenue growth and margin upticks are promising, bu

2025-05-06 08:00:00 - seekingalpha.com

Is Trending Stock Amgen Inc. (AMGN) a Buy Now?

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

2025-05-05 10:00:56 - zacks.com